ResMed, Inc.

Equities

RMD

US7611521078

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX Other stock markets 10:46:35 2024-04-26 am EDT			5-day change	1st Jan Change
213.9 ^USD	+16.64%		+19.61%	+24.36%

04:36pm	Jefferies Adjusts Price Target on ResMed to $180 From $164	MT
03:09pm	Oppenheimer Adjusts ResMed Price Target to $200 From $205, Maintains Outperform Rating	MT

ResMed Inc. Reports Earnings Results for the Fourth Quarter Ended June 30, 2022

August 11, 2022 at 04:05 pm EDT

ResMed Inc. reported earnings results for the fourth quarter ended June 30, 2022. For the fourth quarter, the company reported sales was USD 914.74 million compared to USD 876.1 million a year ago. Net income was USD 195.06 million compared to USD 195.1 million a year ago. Basic earnings per share from continuing operations was USD 1.33 compared to USD 1.34 a year ago. Diluted earnings per share from continuing operations was USD 1.33 compared to USD 1.33 a year ago.

Latest news about ResMed, Inc.

Jefferies Adjusts Price Target on ResMed to $180 From $164	10:36am	MT
Oppenheimer Adjusts ResMed Price Target to $200 From $205, Maintains Outperform Rating	09:09am	MT
JPMorgan Adjusts Price Target on ResMed to $225 From $198	09:00am	MT
Mizuho Adjusts Price Target on ResMed to $220 From $215	08:09am	MT
Needham Adjusts Price Target on ResMed to $236 From $224	08:01am	MT
Morgan Stanley Adjusts Price Target on ResMed to $219 From $207	06:40am	MT
RBC Adjusts Price Target on ResMed to $200 From $187	06:18am	MT
ResMed Declares Quarterly Dividend as Fiscal Q3 Profit Jumps 29%; Shares Up 7%	11:21pm	MT
ResMed tops quarterly profit estimates on strong demand for sleep apnea devices	06:12pm	RE
ResMed Fiscal Q3 Non-GAAP Earnings, Revenue Increase; Shares Rise After Hours	Apr. 25	MT
Transcript : ResMed Inc., Q3 2024 Earnings Call, Apr 25, 2024	Apr. 25
ResMed Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	Apr. 25	CI
ResMed Inc. Declares Quarterly Cash Dividend, Payable on June 13, 2024	Apr. 25	CI
Wall St set for higher open on megacaps boost; earnings, Fed comments on tap	Apr. 17	RE
Needham Adjusts ResMed's Price Target to $224 From $180, Maintains Buy Rating	Apr. 01	MT
ResMed Inc. Announces the U.S. Launch of the AirFit F40	Mar. 06	CI
Morgan Stanley Adjusts Resmed’s Price Target to AU$31.80 From AU$28.60, Keeps at Overweight	Mar. 05	MT
Evans & Partners Upgrades ResMed to Positive From Neutral, Price Target is AU$31	Mar. 04	MT
FTSE 100 Edges Higher on Leap Day, Boosted by Howden Joinery, Haleon Gains	Feb. 29	DJ
Australia shares slip as biotech firm CSL slumps on failed drug trial (Feb 12)	Feb. 11	RE
Powell, the paper tiger	Feb. 05
ANALYST RECOMMENDATIONS : Abbvie, Microsoft, Tesla, Alphabet, Booking...	Feb. 05
Mizuho Adjusts Price Target on ResMed to $215 From $195, Keeps Buy Rating	Jan. 30	MT
Oppenheimer Raises ResMed Price Target to $205 From $185, Maintains Outperform Rating	Jan. 30	MT
UBS Adjusts ResMed Price Target to $180 From $175, Maintains Neutral Rating	Jan. 25	MT

Chart ResMed, Inc.

Duration

Period

More charts

Company Profile

ResMed, Inc. specializes in designing, manufacturing and marketing respiratory disorders diagnosis, treatments and management (primarily sleep respiratory disorders). Net sales break down by family of products as follows: - medical devices (50.4%); - masks (37.9%); - software as a service (11.7%). At the end of June 2021, the group had 6 production sites located in the United States (2), Australia, China, Singapore and Malaysia. The United States accounts for 61.4% of net sales.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-13 - RBC Capital Markets Global Healthcare Conference

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ResMed, Inc. continues to make headway in the sleep market

December 11, 2023 at 05:55 am EST

More Strategies

Ratings for ResMed, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

183.4 USD

Average target price

208.6 USD

Spread / Average Target

+13.72%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
RESMED, INC.	+24.36%	26.94B
THERMO FISHER SCIENTIFIC	+7.93%	218B
DANAHER CORPORATION	+6.21%	182B
INTUITIVE SURGICAL, INC.	+11.60%	132B
BOSTON SCIENTIFIC CORPORATION	+27.23%	108B
EDWARDS LIFESCIENCES CORPORATION	+12.15%	52.98B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-1.89%	47.59B
AGILENT TECHNOLOGIES, INC.	-1.02%	39.96B
GE HEALTHCARE TECHNOLOGIES INC.	+11.14%	39.22B
ILLUMINA, INC.	-11.86%	19.28B

Other Advanced Medical Equipment & Technology